---
schema_version: "secwatch.filing_event.v1"
accession: "0001439725-25-000003"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:21:08.443399+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q2 revenue up 12% to $20M; gross margin 80%; reaffirms FY guidance $80-85M

## Summary
- Q2 revenue $20.0M (+12% YoY); Lung Diagnostic $17.9M (+8%), Development Services $2.1M (+53%).
- Gross margin 80% (up 150 bps); net loss $11.5M (+6% YoY); Adjusted EBITDA loss $7.2M.
- Reaffirms FY2025 revenue guidance $80-85M; aims for Adjusted EBITDA positive in Q4.
- Sales team expanded to 74 reps (+21% YoY); primary care ordering up >100%; digital ordering up 63%.
- Development services dollars under contract $12.5M (+54% YoY); ALTITUDE trial enrollment complete.

## SEC filing metadata
- accession: 0001439725-25-000003
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000143972525000003/0001439725-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000143972525000003/bdsx-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439725-25-000003
- JSON: https://secwatch.observer/filing/0001439725-25-000003.json
- Plain text: https://secwatch.observer/filing/0001439725-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.